Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Pain
Interventions: Transcutaneous Electrical Nerve Stimulation (TENS); Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: New Haven, Connecticut • New York, New York

Conditions: Port Wine Stains
Interventions: Rapamycin cream, Pulsed dyed laser; Drug · Procedure
Lead sponsor: AFT Pharmaceuticals, Ltd.; Industry
Eligibility: Up to 10 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Corpus Christi, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium Inhalation Solution, Placebo; Drug · Other
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 983 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 12
States / cities: Los Angeles, California • Pismo Beach, California • San Diego, California + 9 more

Conditions: Alzheimer's Disease
Interventions: KarXT, KarX-EC, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 28
States / cities: Long Beach, California • Redlands, California • Basalt, Colorado + 24 more

Conditions: Diabetes Mellitus, Type 2, Obesity
Interventions: Placebo, BI 10773; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 26
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 23 more

Conditions: Posterolateral Thoracotomy, Postoperative Pain
Interventions: EXPAREL 266 mg, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Miami, Florida • Shreveport, Louisiana • Fargo, North Dakota + 4 more

Conditions: Small Cell Lung Cancer
Interventions: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI); Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 35
States / cities: Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more

Conditions: Atopic Dermatitis
Interventions: Montelukast, Placebo; Drug
Lead sponsor: 1st Allergy & Clinical Research Center; Other
Eligibility: 1 Year to 8 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Centennial, Colorado • Thornton, Colorado

Conditions: Gastrointestinal Disease Symptoms
Interventions: Prebiotic, probiotic, postbiotic combination, Placebo; Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Asthma
Interventions: Fluticasone propionate/Formoterol fumarate 250/10, Placebo, Fluticasone propionate/Formoterol fumarate 100/10, Fluticasone propionate 250, Formoterol fumarate 10; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 62
States / cities: Pell City, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more

Conditions: Healthy Participants, Atopic Dermatitis
Interventions: PF-07832837, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Anaheim, California • San Diego, California • Miami, Florida + 2 more

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo, fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 923 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 41
States / cities: Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more

Conditions: Healthy Volunteers
Interventions: NasoShield, Placebo; Biological · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia, Ulcers
Interventions: HGF plasmid, Placebo; Genetic
Lead sponsor: AnGes USA, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 4
States / cities: Pensacola, Florida • Indianapolis, Indiana • Boston, Massachusetts + 1 more

Conditions: Pertrochanteric Fracture
Interventions: Marcaine, Duramorph , ketorolac, Bupivacaine (Marcaine), General Anesthetics; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Allergic Conjunctivitis
Interventions: contact lens with ketotifen, contact lens; Device
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 8 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Colon Cancer, Gastrointestinal Cancer
Interventions: PoZibio, Inert placebo; Dietary Supplement
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 329 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Allergy
Interventions: Xolair (omalizumab); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Obesity, Heart Failure, Diastolic, Metabolic Syndrome
Interventions: High intensity exercise, Omega-3 fish oil, Yoga, olive oil capsules; Behavioral · Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 40 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pain, Postoperative Pain, Pain, Acute
Interventions: MR-107A-01, Placebo; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Myofascial Pain Syndrome
Interventions: Capsaicin, Placebo; Drug
Lead sponsor: Stamford Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Stamford, Connecticut

Conditions: Liver Cirrhosis
Interventions: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Englewood, Colorado • Charleston, South Carolina • San Antonio, Texas

Conditions: Atrial Fibrillation
Interventions: BAY 3670549, Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 5 more

Search by objective public record fields.

Transcutaneous Electrical Nerve Stimulation (TENS) for IUD Insertion Pain

Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains

Tiotropium / Respimat One-Year Study

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens

Ritual Synbiotic+, a Dietary Supplement Designed to Impact Gastrointestinal Health, Mood, and Behavior in Women

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.

NasoShield in Healthy Adults to Study Safety and Immunogenicity

Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

Effects of a Surgical Site Injection on Pain Scores and Narcotic Use After Orthopaedic Trauma Surgery

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

Postbiotics for Mitigation of Postoperative Dysbiosis in Gastrointestinal Cancer Surgery

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

A Safety and Efficacy Study of Xolair in Peanut Allergy

Improving Metabolic Health in Patients With Diastolic Dysfunction

Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain

Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation